These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 25573772)

  • 1. Canada's Patented Medicines (Notice of Compliance) Proceedings and Intellectual Property.
    Bian H; McCourt C
    Cold Spring Harb Perspect Med; 2015 Jan; 5(6):. PubMed ID: 25573772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bill C-30: who wins and who loses in Canada's pharmaceutical patent battles?
    Hollis A
    Expert Opin Ther Pat; 2018 Jan; 28(1):1-3. PubMed ID: 28974123
    [No Abstract]   [Full Text] [Related]  

  • 3. Canada's patented medicine notice of compliance regulations: balancing the scales or tipping them?
    Lexchin J
    BMC Health Serv Res; 2011 Mar; 11():64. PubMed ID: 21435247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intellectual property rights and the Canadian pharmaceutical marketplace: where do we go from here?
    Lexchin J
    Int J Health Serv; 2005; 35(2):237-56. PubMed ID: 15932005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canada's laws on pharmaceutical intellectual property: the case for fundamental reform.
    Grootendorst P; Bouchard R; Hollis A
    CMAJ; 2012 Mar; 184(5):543-9. PubMed ID: 22065362
    [No Abstract]   [Full Text] [Related]  

  • 6. Canada ordered to implement WTO ruling against "stockpiling" of generic drugs.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2000; 5(4):27. PubMed ID: 11833161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical patent law: the Canadian perspective.
    Aumand L; Norman J
    Pharm Pat Anal; 2016 Jul; 5(4):271-9. PubMed ID: 27346187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Specificities of patent protection in the pharmaceutical industry: modalities and traits of intellectual property].
    Jannuzzi AH; Vasconcellos AG; de Souza CG
    Cad Saude Publica; 2008 Jun; 24(6):1205-18. PubMed ID: 18545747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed WTO ruling on generic drug development.
    Elliott R
    Can HIV AIDS Policy Law Newsl; 2000; 5(2-3):38-42, 40-4. PubMed ID: 11833195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
    Higgins MJ; Graham SJ
    Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
    [No Abstract]   [Full Text] [Related]  

  • 12. Canada and access to medicines in developing countries: intellectual property rights first.
    Lexchin J
    Global Health; 2013 Sep; 9():42. PubMed ID: 24007595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States.
    Son KB; Lopert R; Gleeson D; Lee TJ
    Global Health; 2018 Oct; 14(1):101. PubMed ID: 30355313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Panel rules against Canada on patent terms for pre-TRIPS patents.
    Elliott R
    Can HIV AIDS Policy Law Newsl; 2000; 5(2-3):43, 45. PubMed ID: 11833196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development.
    Matthews JH
    Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIPS from Doha to Cancún ... to Ottawa: global developments in access to treatment and Canada's Bill C-56.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2003 Dec; 8(3):1, 7-18. PubMed ID: 15104062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethical and intellectual property in the biological sciences.
    Maher EA
    Cell Mol Biol (Noisy-le-grand); 1997 May; 43(3):263-7. PubMed ID: 9193780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patent law protection of inventions in medicine and pharmaceutical industry.
    Miladinović Z; Varga S; Radojković M
    Vojnosanit Pregl; 2013 Jun; 70(6):600-5. PubMed ID: 23885528
    [No Abstract]   [Full Text] [Related]  

  • 19. [Patents on life? No patent on life!].
    van Raden L
    Dtsch Tierarztl Wochenschr; 1998 Mar; 105(3):90-3. PubMed ID: 9581373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Removing barriers? An overview of the Canadian Access to Medicines Regime.
    Penner MD; Armstrong PG
    Health Law Can; 2008 Jun; 28(3-4):112-22. PubMed ID: 19051971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.